Saturday, September 7, 2024
9/7/2024
Project Summary and Abstract Chimeric antigen receptor (CAR) T cells are genetically engineered T lymphocytes designed to sense antigens and mount an immune response. Though CAR T cells have received FDA approval for the treatment of several hematologic malignancies, success in solid tumors is limited by the immunosuppressive tumor microenvironment, and treatment-limiting adverse effects such as on-target, off-tumor toxicity and cytokine release syndrome. Though investigators report strategies for mitigating these limitations such as biomaterials for reshaping the tumor microenvironment, and logic-gated CAR T cells to prevent non-specific toxicity, no proposed strategy has overcome each of these barriers. To surmount these limitations, I propose the use of a novel self- assembled hydrogel for implantation into tumor. This hydrogel will be used in conjunction with a split CAR T cell called a zipCAR, which uses a split adaptor protein (zipFv) to sense antigens. The hydrogel is composed of a 4 arm PEG linker decorated with leucine zippers that can be loaded with zipCargo proteins (payload proteins that are modified with a leucine zipper, including zipFv). The hydrogel supplies the zipFv adaptor protein, cytokines (IL-7), and chemokines (CXCL9). I hypothesize that the use of this in situ hydrogel will overcome the barriers to CAR T cell therapy in solid tumors by: 1) opposing T cell anergy and promoting proliferation in the resection cavity; 2) preventing antigen escape via encapsulation of zipFvs targeting multiple antigens; and, 3) imparting spatiotemporal control over CAR T cell activity. Aim 1 will demonstrate the advantage of the hydrogel by monitoring CAR T cell migration and proliferation in a murine model of ROR1+ lung cancer. Aim 2 will document the efficacy and safety advantages of the hydrogels in a toxicity model of lung cancer. To demonstrate prevention of antigen escape, ROR1- and MSLN-deficient lung cancer cell lines will be created using CRISPR-Cas9 knockouts. In a murine model of antigen escape, these cells will be used to demonstrate superior efficacy in mice treated with zipCAR T cells and hydrogels loaded with zipFvs against both antigens. This proposal builds around five key components of critical research and clinical skills to support my development into an independent engineer/scientist: (1) an interdisciplinary research project focusing on novel surgical biomaterials for enhancement of CAR T cell activity; (2) multi-disciplinary mentoring from Drs. Grinstaff (biomaterials), Wong (immunotherapy); and, Colson (clinical medicine, animal models, and immunology), (3) academic engineer-scientist in research conduct and communication skills, (4) clinical awareness program, overseen by Dr. Yolonda Colson a nationally recognized surgeon, and (5) professional development activities to guide my training goals.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
